# XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

> **NCT05038644** · PHASE1 · TERMINATED · sponsor: **Ehab L Atallah** · enrollment: 22 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- T Cell Acute Lymphoblastic Leukemia
- T Cell Lymphoblastic Lymphoma

## Interventions

- **DRUG:** XmAb18968 - Dose level -1
- **DRUG:** XmAb18968 - Dose level 0 (starting dose)
- **DRUG:** XmAb18968 - Dose level 1
- **DRUG:** XmAb18968 - Dose level 2
- **DRUG:** XmAb18968 - Dose level 3

## Key facts

- **NCT ID:** NCT05038644
- **Lead sponsor:** Ehab L Atallah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-02
- **Primary completion:** 2024-04-24
- **Final completion:** 2024-11-18
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Drug expired May 31, 2024.
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05038644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05038644, "XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05038644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*